doxorubicin cardiomyopathy
Conditions
Interventions
None listed
Sponsors
Yamaguchi University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria (All of the following must be met): 1)Individuals aged 16 years or older at the time of obtaining informed consent 2)No restrictions based on sex 3)Patients scheduled to receive doxorubicin-based chemotherapy for malignant lymphoma in the Third Department of Internal Medicine at Yamaguchi University Hospital 4)Patients who have undergone, or are scheduled to undergo, echocardiography within six months prior to the initial administration of doxorubicin 5)Patients (or their legally authorized representatives) who have received sufficient explanation regarding participation in this study and have provided written informed consent based on adequate understanding and voluntary agreement
Exclusion criteria
Exclusion criteria: 1)Patients with a history of prior treatment with anthracycline-based anticancer agents 2)Patients who, prior to the initial administration of doxorubicin, have a left ventricular ejection fraction (LVEF) of less than 50%, or exhibit symptoms suggestive of heart failure according to the Framingham criteria 3)Patients deemed unsuitable for participation in this study by the principal investigator or co-investigators for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will investigate the incidence of doxorubicin-induced cardiomyopathy, divide patients into those who developed doxorubicin-induced cardiomyopathy and those who did not, and exploratory study the correlation with patient background, echocardiographic findings, and blood test findings. | — |
Countries
Japan
Contacts
Public ContactYoshihide Nakamura
Yamaguchi University Graduate School of Medicine Division of Cardiology, Department of Medicine and Clinical Science
Outcome results
None listed